0.17
+0(+0.00%)
Currency In USD
| Previous Close | 0.17 |
| Open | 0.17 |
| Day High | 0.17 |
| Day Low | 0.17 |
| 52-Week High | 4.55 |
| 52-Week Low | 0.12 |
| Volume | 820 |
| Average Volume | 42,534 |
| Market Cap | 1.5M |
| PE | 0.47 |
| EPS | 0.36 |
| Moving Average 50 Days | 0.16 |
| Moving Average 200 Days | 0.67 |
| Change | 0 |
If you invested $1000 in Bio-Path Holdings, Inc. (BPTH) 10 years ago, it would be worth $0.04 as of June 01, 2025 at a share price of $0.17. Whereas If you bought $1000 worth of Bio-Path Holdings, Inc. (BPTH) shares 5 years ago, it would be worth $1.63 as of June 01, 2025 at a share price of $0.17.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025
GlobeNewswire Inc.
May 22, 2025 8:30 PM GMT
HOUSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity
Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
GlobeNewswire Inc.
May 01, 2025 11:00 AM GMT
Data suggest BP1001-A prevents fatty acid-induced insulin resistance in cellsHOUSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antis
Bio-Path Holdings Reports Full Year 2024 Financial Results
GlobeNewswire Inc.
Mar 28, 2025 11:00 AM GMT
Reports Continued Progress Across Both Obesity and Oncology FranchisesHOUSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle techn